HALUCENEX LIFE SCIENCES

Creso’s acquisition target Halucenex to extend clinical trials beyond veterans

Finfeed Archived Jun 08, 2021

Creso Pharma's (ASX: CPH) targeted acquisition company Halucenex intends to expand its phase II clinical trial to include non-veterans.

Creso Pharma’s Halucenex engages HeteroGeneity ahead of US entry

Finfeed Archived May 26, 2021

Creso Pharma's target acquisition group Halucenex has entered into an agreement with consultancy group, HetereoGeneity

CPH just picked up 10 grams of pharma grade psilocybin

Next Investors May 14, 2021

Creso Pharma (ASX: CPH)’s acquisition target Halucenex just picked up an extra 10g of ‘hard-to-access’ synthetic psilocybin - and now has 22.3g in total.

Creso Pharma’s target acquisition company announces expansion into other psychedelic compounds

Finfeed Archived Apr 12, 2021

Creso Pharma Limited (ASX: CPH, FRA:1X8) has provided an update regarding target acquisition company, Halucenex Life Sciences, outlining its entry into an advisory agreement with Growing Together Research Inc. (GTR) to explore the genome sequencing of natural psilocybe.

Halucenex prepares for PTSD clinical trials

Finfeed Archived Mar 17, 2021

Creso Pharma's targeted acquisition, Halucenex Life Sciences has appointed True North Clinical Research to conduct PTSD trials